ScholarIQanswers from OpenAlex
Otsuka Pharmaceutical Development and Commercialization
FunderResearch funding and supported work
Otsuka Pharmaceutical Development and Commercialization is a funder indexed in ScholarIQ from OpenAlex.
How many works does Otsuka Pharmaceutical Development and Commercialization have?
ScholarIQindexed works
Otsuka Pharmaceutical Development and Commercialization has 269 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Otsuka Pharmaceutical Development and Commercialization?
ScholarIQopenalex
The OpenAlex for Otsuka Pharmaceutical Development and Commercialization is on the source record.
What are the most-cited papers on Otsuka Pharmaceutical Development and Commercialization?
ScholarIQmost cited works
CKD progression, kidney failure, and mortality among US patients with IgA nephropathy
John J. Sim, Qiaoling Chen, Nancy Cannizzaro, Ancilla W. Fernandes, Cibele S. Pinto, Simran K. Bhandari, John Chang, Asher D. Schachter, Mohit Mathur
Incidence and Proportion of Primary Focal Segmental Glomerulosclerosis (FSGS) among a Racially and Ethnically Diverse Adult Patient Population between 2010 and 2021
Mercedes A. Munis, Qiaoling Chen, Matt Hill, Min Zhuo, Asher D. Schachter, Simran K. Bhandari, Aviv Hever, Teresa N. Harrison, Ancilla W. Fernandes, John J. Sim
Mortality risk in patients with autosomal dominant polycystic kidney disease
Deirdre Mladsi, Xiaolei Zhou, Gregory Mader, Myrlene Sanon, Jinyi Wang, Christine Barnett, Cynthia Willey, Stephen L. Seliger
The incidence and prevalence of immunoglobulin A nephropathy in the United States
Marc DeCongelio, Sarah Ali, Martina Furegato, Sandipan Bhattacharjee, Ancilla W. Fernandes
Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease
Dorothee Oberdhan, Aaron Yarlas, Jakob Bue Bjørner, Holly B. Krasa